GlassScriptPhysician profile
Caroline Mercer Bulger
NPI 1588291025
$858.67
in general payments reported to CMS, 2019-2025
12 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $83.10 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $231.95 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $88.30 | 2024-2025 | Myfembree, Gemtesa |
| Supernus Pharmaceuticals, INC. | $86.01 | 2025 | Qelbree |
| Boston Scientific Corporation | $81.76 | 2025 | General - Female Sui |
| Astellas Pharma US INC | $56.76 | 2025 | Veozah |
| Organon LLC | $52.70 | 2024-2025 | Jada System |
| Pfizer INC. | $50.20 | 2025 | |
| Novo Nordisk INC | $48.41 | 2025 | Wegovy |
| Lilly USA, LLC | $44.85 | 2025 | Zepbound, Mounjaro |
| Millicent US INC | $41.07 | 2025 | Femlyv |
| Mayne Pharma Commercial LLC | $40.12 | 2025 | |
| Exeltis, USA INC. | $36.54 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Bulger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.